EDP 514
Alternative Names: EDP-514Latest Information Update: 02 Jun 2025
At a glance
- Originator Enanta Pharmaceuticals
- Class Antivirals; Hepatoprotectants; Small molecules
- Mechanism of Action RNA-directed DNA polymerase inhibitors; Viral core protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Hepatitis B
Most Recent Events
- 15 Nov 2024 Pharmacokinetics data from preclinical trials in Hepatitis B presented at The Liver Meeting 2024: 75th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2024)
- 10 Oct 2023 EDP 514 is still in phase I trials for Hepatitis B in Hong Kong, Taiwan and US (Enanta Pharmaceuticals pipeline, September 2023)
- 28 Aug 2023 No recent reports of development identified for phase-I development in Hepatitis-B in Hong Kong (PO, Capsule)